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parenteral gold therapy, methotrexate, 
glucocorticoids, chloroquine, and nonste-
roidal anti-inflammatory drugs. He had 
also undergone sympathectomy. Physical 
exam revealed scarring ulcers in both 
hands, severely decreased movements in the 
large joints bilaterally, and ulnar deviation. 
Laboratory tests showed elevated erythro-
cyte sedimentation rate (ESR) at 52 mm/h, 
leukocytosis (22.7 × 109/L); rheumatoid fac-
tor (RF) and anti-cyclic citrullinated peptide 
antibodies (anti-CPP) were negative.
Lung ultrasound showed right pleural 
effusion, and about 700 ml of fluid were 
drained and examined for atypical cells and 
Mycobacterium tuberculosis with negative 
results. X-ray of the hands revealed signs 
of 2nd–3rd stage RA with destruction of 
the second right finger’s metacarpal head 
A 44 year old man presented to the Rheumatology Department of Semey 
State Medical University Medical Center 
complaining of general weakness, joint 
pain (especially in the large joints and in 
the lumbar region), morning stiffness of up 
to 2 hours, loss of appetite, right sided chest 
pain, and fever (39°C).
He had been diagnosed with rheumatoid 
arthritis (RA) 9 years before and had had 
severe Raynaud’s syndrome with digital 
ulcerations for the past 5 years. During 
the course of those 9 years he had received 
[Figure 1]. X-ray of the knees also demon-
strated signs of 2nd stage RA.
After screening the patient for hepatitis 
B and C as well as for tuberculosis with 
negative results, rituximab was given in two 
500 mg intravenous infusions 2 weeks apart. 
Following the rituximab infusions, the 
patient received methotrexate 10 mg weekly 
for 2 months and prednisone 5 mg daily.
In the following months, the number 
of tender and swollen joints markedly 
decreased. The patient resumed physical 
activity and ESR went down to normal (3 
mm/h). The Das-28 score went from 6.31 to 
1.61, and the severity of pain decreased to 2 
from an initial score of 9–10 on the Visual 
Analog Scale. The patient continues to be in 
remission 8 years later, and an X-ray of the 
hands has shown stability [Figure 2].
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Figure 1. X-ray of the hands at presentation Figure 2. X-ray of the hands 8 years later
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In RA cases resistant to methotrexate 
and anti-tumor necrosis factor agents, ritux-
imab is generally administered at a dose of 
1 gram followed by another dose after a 
fortnight (independent of body weight). 
However a meta-analysis published in 2014 
showed that a lower-dose regimen (500 mg) 
of rituximab has similar effectiveness [1].
Considering its lower cost, we used this 
reduced dose in our patient with very good 
outcome. Rituximab seems to be most effec-
tive in seropositive patients [2]. It worked 
well in our case even though the patient 
was seronegative, and the DAS-28 score [3] 
markedly decreased. 
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Type 1 diabetes (T1D) is an autoimmune disease that 
results from the destruction of pancreatic β-cells by the 
immune system that involves innate and adaptive immune 
cells. Mucosal-associated invariant T cells (MAIT cells) are 
innate-like T-cells that recognize derivatives of precursors of 
bacterial riboﬂavin presented by the major histocompatibility 
complex (MHC) class I-related molecule MR1. Since T1D is 
associated with modiﬁcation of the gut microbiota, Rouxel 
and collaborators investigated MAIT cells in this pathology. 
In patients with T1D and mice of the non-obese diabetic 
(NOD) strain, the authors detected alterations in MAIT cells, 
including increased production of granzyme B, which occurred 
before the onset of diabetes. Analysis of NOD mice that were 
deﬁcient in MR1, and therefore lacked MAIT cells, revealed 
a loss of gut integrity and increased anti-islet responses 
associated with exacerbated diabetes. Together the data 
highlight the role of MAIT cells in the maintenance of gut 
integrity and the control of anti-islet autoimmune responses. 
Monitoring of MAIT cells might represent a new biomarker 
of T1D, while manipulation of these cells might open new 
therapeutic strategies.
 
Nature Immunol 2017; 18: 1321
Eitan Israeli
Capsule
Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes
Macfarlane and colleagues tried to estimate the proportion 
of patients with axial spondyloarthritis (SpA) in a UK national 
biologics registry who met criteria for ﬁbromyalgia, and 
to delineate the characteristics of these patients. Of the 
patients registered in the British Society for Rheumatology 
Biologics Register in Ankylosing Spondylitis (BSRBR-AS), 1504 
(68% male) were eligible for the current analysis, of whom 
311 (20.7%) met the 2011 research criteria for ﬁbromyalgia. 
Prevalence of ﬁbromyalgia was similar between patients 
who fulﬁlled the modiﬁed New York criteria for ankylosing 
spondylitis (AS) (19.7%) and those who fulﬁlled Assessment 
of SpondyloArthritis international Society (ASAS) imaging 
criteria but not the modiﬁed New York criteria (25.2%); 
however, among those who fulﬁlled only the ASAS clinical 
criteria, the prevalence of FM was lower (9.5%). Patients who 
met ﬁbromyalgia criteria reported signiﬁcantly worse disease 
activity, function, global severity scores, and quality of life, and 
were more likely to have moderate or severe levels of mood 
disorder and clinically important fatigue. Patients who met 
ﬁbromyalgia criteria reported experiencing work impairment 
around half their working time. Meeting ﬁbromyalgia criteria 
was not related to elevated C-reactive protein levels or most 
extraspinal manifestations, but was associated with a higher 
likelihood of having received biologic therapy. Developing 
management approaches that would address the signiﬁcant 
unmet clinical needs of the 1 in 5 patients with axial SpA who 
meet criteria for FM should be a research priority.
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“After you understand about the sun and the stars and the rotation of the earth, you may still 
miss the radiance of the sunset”
Alfred North Whitehead, (1861–1947), English mathematician and philosopher best known as the deﬁning ﬁgure of the 
philosophical school known as process philosophy
